PIM1 inhibitor synergizes the anti-tumor effect of osimertinib via STAT3 dephosphorylation in EGFR-mutant non-small cell lung cancerZiyi Sun(Hunan Cancer Hospital), Nong Yang(Hunan Cancer Hospital)Annals of Translational MedicineMarch 1, 202010.21037/atm.2020.02.43Cited by 17SaveCiteExport RISWatch citationsRelated PapersMast cells induce epithelial-to-mesenchymal transition and migration in non-small cell lung cancer through IL-8/Wnt/β-catenin pathway|Journal of Cancer|2019|21Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study|BMC Cancer|2022|19